Summary of Product Characteristics (SmPC) - Carbimazole 10 mg tablets
1 NAME OF THE MEDICINAL PRODUCT
Carbimazole 10mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10mg of carbimazole.
Excipient(s) with known effect
Lactose monohydrate (97.175mg per tablet)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Pink, mottled, round, biconvex uncoated tablets, debossed with "10" on one side and plain on other side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Carbimazole is an anti-thyroid agent. It is indicated in adults and children in all conditions where reduction of thyroid function is required. Such conditions are:
- 1. Hyperthyroidism.
- 2. Preparation for thyroidectomy in hyperthyroidism.
- 3. Therapy prior to and post radio-iodine treatment.
4.2 Posology and method of administration
Posology
Carbimazole should only be administered if hyperthyroidism has been confirmed by laboratory tests.
Adults
The initial dose is in the range 20 - 60 mg, taken as two to three divided doses. The dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism. Subsequent therapy may then be administered in one of two ways.
Maintenance regimen: Final dosage is usually in the range 5 - 15 mg per day, which may be taken as a single daily dose. Therapy should be continued for at least six, and up to eighteen months.
Serial thyroid function is recommended, together with appropriate dosage modification in order to maintain a euthyroid state.
Blocking-replacement regimen: Dosage is maintained at the initial level, i.e. 20 - 60 mg per day, and supplemental l-thyroxine, 50 - 150 mcg per day, is administered concomitantly, in order to prevent hypothyroidism. Therapy should be continued for at least six months and up to eighteen months.
Where a single dosage of less than 20 mg is recommended, it is intended that Carbimazole 5 mg tablets should be taken.
Elderly
No special dosage regimen is required, but care should be taken to observe the contra-indications and warnings as it has been reported that the risk of a fatal outcome to neutrophil dyscrasia may be greater in the elderly (aged 65 and over).
Paediatric population
Use in children and adolescents (3 to 17 years of age)
The usual initial daily dose is 15 mg per day adjusted according to response.
Use in children (2 years of age and under)
Safety and efficacy of carbimazole in children below 2 years of age have not been evaluated systematically. Use of carbimazole in children below 2 years of age is therefore not recommended.
Method of administration
Oral
4.3 Contraindications
Carbimazole is contraindicated in patients with:
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Serious pre-existing haematological conditions
- Severe hepatic insufficiency
- Patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole.
4.4 Special warnings and precautions for use
Bone marrow depression including neutropenia, eosinophilia, leucopenia and agranulocytosis has been reported. Fatalities with carbimazole-induced agranulocytosis have been reported.
Rare cases of purpura, anaemia, pancytopenia/aplastic anaemia and isolated thrombocytopenia have also been reported. Additionally, very rare cases of haemolytic anaemia have been reported.
Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever and malaise and should be instructed to stop the drug and to seek medical advice immediately. In such patients, white blood cell counts should be performed immediately, particularly where there is any clinical evidence of infection.
Following the onset of any signs and symptoms of hepatic disorder (pain in the upper abdomen, anorexia, general pruritus) in patients, the drug should be stopped and liver function tests performed immediately.
Early withdrawal of the drug will increase the chance of complete recovery.
Carbimazole should be used with caution in patients with mild-moderate hepatic insufficiency. If abnormal liver function is discovered, the treatment should be stopped. The half-life may be prolonged due to liver disorder.
Patients unable to comply with the instructions for use or who cannot be monitored regularly should not be treated with carbimazole.
Regular full blood count checks should be carried out in patients who may be confused or have a poor memory.
Carbimazole should be stopped temporarily at the time of administration of radio-iodine, to avoid thyroid crisis.
Precaution should be taken in patients with intrathoracic goitre, which may worsen during initial treatment with carbimazole. Tracheal obstruction may occur due to intrathoracic goitre.
The use of carbimazole in non-pregnant women of childbearing potential should be based on individual risk/benefit assessment (see section 4.6).
There is risk of cross-allergy between carbimazole, thiamazole and propylthiouracil.
There have been post-marketing reports of acute pancreatitis in patients receiving carbimazole or its active metabolite thiamazole. In case of acute pancreatitis, carbimazole should be discontinued immediately. Carbimazole must not be given to patients with a history of acute pancreatitis after administration of carbimazole or its active metabolite thiamazole. Re-exposure may result in recurrence of acute pancreatitis, with decreased time to onset.
Excessive dosing may result in subclinical or clinical hypothyroidism and goitre growth, due to increased TSH. Therefore, the dose of carbimazole should be reduced as soon as a euthyroid metabolic state is achieved and levothyroxine should be given in addition if necessary. It is not useful to discontinue thiamazole completely and continue levothyroxine alone. The growth of a goitre during carbimazole therapy, despite TSH inhibition, is a result of the underlying disease and cannot be prevented by additional levothyroxine treatment.
Women of childbearing potential and pregnancy
Women of childbearing potential have to use effective contraceptive measures during treatment.
The use of carbimazole in pregnant women must be based on the individual benefit/risk assessment. If carbimazole is used during pregnancy, the lowest effective dose without additional administration of thyroid hormones should be administered. Close maternal, foetal and neonatal monitoring is warranted (see section 4.6).
Carbimazole contains lactose
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Little is known about interactions.
Interaction studies have not been performed in paediatric patients.
Particular care is required in case of concurrent administration of medication capable of inducing agranulocytosis.
Since carbimazole is a vitamin K antagonist, the effect of anticoagulants could be intensified. Additional monitoring of PT/INR should be considered, especially before surgical procedures.
The serum levels of theophylline can increase and toxicity may develop if hyperthyroidic patients are treated with antithyroid medications without reducing the theophylline dosage.
Co-administration of prednisolone and carbimazole may result in increased clearance of prednisolone.
Carbimazole may inhibit the metabolism of erythromycin, leading to reduced clearance of erythromycin.
Serum digitalis (digoxin) levels may be increased when hyperthyroid patients on a stable digitalis glycoside (digoxin) regimen become euthyroid; a reduced dosage of digitalis glycosides(digoxin) may be needed.
Hyperthyroidism may cause an increased clearance of beta-adrenergic blockers with a high extraction ratio. A dose reduction of beta blockers may be needed when a hyperthyroid patient becomes euthyroid.
4.6 Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential have to use effective contraceptive measures during treatment (see section 4.4).
Pregnancy
Carbimazole crosses the placenta but, provided the mother’s dose is within the standard range, and her thyroid status is monitored; there is no evidence of neonatal thyroid abnormalities.
Studies have shown that the incidence of congenital malformations is greater in the children of mothers whose hyperthyroidism has remained untreated than in those who have been treated with carbimazole.
However, very rare cases of congenital malformations have been observed following the use of carbimazole or its active metabolite methimazole during pregnancy.
A causal relationship of these malformations, especially choanal atresia and aplasia cutis congenital (congenital scalp defects), to transplacental exposure to carbimazole and methimazole cannot be excluded. Therefore, the use of carbimazole in non-pregnant women of childbearing potential should be based on individual risk/benefit assessment (see section 4.4).
Cases of renal, skull, cardiovascular congenital defects, exomphalos, gastrointestinal malformation, umbilical malformation and duodenal atresia have also been reported. Therefore, carbimazole should be used in pregnancy only when propylthiouracil is not suitable. If Carbimazole tablet is used in pregnancy the dose of Carbimazole tablet must be regulated by the patient’s clinical condition. The lowest dose possible should be used, and this can often be discontinued three to four weeks before term, in order to reduce the risk of neonatal complications.
The blocking-replacement regimen should not be used during pregnancy since very little thyroxine crosses the placenta in the last trimester. Hyperthyroidism in pregnant women should be adequately treated to prevent serious maternal and foetal complications.
Carbimazole is able to cross the human placenta.
Based on human experience from epidemiological studies and spontaneous reporting, carbimazole is suspected to cause congenital malformations when administered during pregnancy, particularly in the first trimester of pregnancy and at high doses.
Reported malformations include aplasia cutis congenita, craniofacial malformations (choanal atresia; facial dysmorphism), exomphalos, oesophageal atresia, omphalo-mesenteric duct anomaly, and ventricular septal defect.
Carbimazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones. If carbimazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended (see section 4.4).
Breast-feeding
Carbimazole is secreted in breast milk, A risk for the breast-fed child, in particular a risk of hypothyroidism, cannot be excluded. As a precautionary measure, it is recommended not to breast-feed during treatment with Carbimazole Tablet
Fertility
No fertility data available.
4.7 Effects on ability to drive and use machines
Not relevant.
4.8 Undesirable effects
Adverse reactions usually occur in the first eight weeks of treatment. The most frequently occurring reactions are nausea, headache, arthralgia, mild gastric distress, skin rashes and pruritus. These reactions are usually self-limiting and may not require withdrawal of the drug.
The undesirable effects are listed below by system organ class and the following frequency convention:
Rare (≥ 1/10,000 to < 1/1,000),
Very rare (< 1/10,000)
Not known (cannot be estimated from the available data).
| System Organ Class | Frequency | Adverse events |
Blood and lymphatic system disorders | Rare Very rare Not known | Purpura, anaemia, pancytopenia/aplastic anaemia,neutropenia, leucopenia and isolated thrombocytopenia have also been reported. Haemolytic anaemia Bone-marrow failure, including neutropenia and agranulocytosis have been reported.Lymphadenopathy |
| Immune system disorders | Not known | Angioedema and multiorgan hypersensitivity reactions,such as cutaneous vasculitis, liver, lung and renal effects occur |
| Endocrine disorders | Not known | Insulin autoimmune syndrome (with pronounced decline in blood glucose |
| levels) | ||
| Nervous system disorders | Not known | Headache, neuritis, polyneuropathy |
| Vascular disorders | Not known | Haemorrhage |
| Gastrointestinal system disorders | Not known | Pancreatitis acute, nausea, mild gastric disorders.ageusia, acute salivary gland swelling |
| Hepatobiliary disorders | Not known | Hepatic disorders, including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported*. |
Skin and subcutaneous tissue disorders | Very rare Not known | Severe cutaneous hypersensitivity reactions in both adult and paediatric patients, including Stevens-Johnsons syndrome**. Skin rash, pruritus, urticaria. Alopecia. |
| Musculoskeletal and connective tissue disorders | Not known | Patients experiencing myalgia after the intake of Carbamazole should have their creatine phosphokinase levels monitored. Isolated cases of myopathy have been reported. |
| General disorders and administration site conditions | Not known | Pyrexia, malaise |
| Injury, poisoning and procedural complications | Not known | Contusion |
Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever and malaise and should be instructed to stop the drug and to seek medical advice immediately. In such patients, blood cell counts should be performed, particularly where there is any clinical evidence of infection.
* in these cases, carbimazole should be withdrawn.
** very rare including isolated reports: severe forms, including generalised dermatitis, have only been described in isolated cases
Paediatric population
Frequency, type and severity of adverse reactions in children appear to be comparable with those in adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow card scheme, Website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Symptoms
No symptoms are likely from a single large dose.
Management
No specific treatment is indicated.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Sulfur-containing imidazole derivatives ATC Code: H03B B01
Mechanism of action:
Carbimazole, a thionamide, is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole, also known as methimazole. The method of action is believed to be inhibition of the organification of iodide and the coupling of iodothyronine residues which in turn suppress the synthesis of thyroid hormones.
5.2 Pharmacokinetic properties
Absorption
Carbimazole is rapidly metabolised to thiamazole. After oral ingestion, peak plasma concentrations of thiamazole, the active moiety, occur at 1 to 2 hours
Distribution
The total volume of distribution of thiamazole is 0.5 1/kg. Thiamazole is concentrated in the thyroid gland. This intrathyroidal concentration of thiamazole has the effect of prolonging its activity. However, thiamazole has a shorter half-life in hyperthyroid patients than in normal controls and so more frequent initial doses are required while the hyperthyroidism is active.
Biotransformation
Thiamazole is moderately bound to plasma proteins.
Carbimazole has a half-life of 5.3 to 5.4 hours. It is possible that the plasma half-life may also be prolonged by renal or hepatic disease. See section 4.2. Thiamazole crosses the placenta and appears in breast milk. The plasma: milk ratio approaches unity.
Elimination
Over 90% of orally administered carbimazole is excreted in the urine as thiamazole or its metabolites. The remainder appears in faeces. There is 10% enterohepatic circulation.
5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate
Ferric oxide red [E172]
Croscarmellose sodium
Magnesium stearate
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
Blister Pack: 2 years
HDPE Container Pack: 2 years
Shelf life after opening of container: 100 days
6.4 Special precautions for storage
Store below 30°C
6.5 Nature and contents of container
Blister packs: Blister pack comprises of White Opaque 250µ PVC as a forming material and Plain 25 µ Aluminium foil/ 6-8 gsm HSL as the lidding material.
Pack size: 20, 30, 50, 100 tablets.
Container Pack: Container pack comprises of round white HDPE bottle, Child resistant closure with pulp & liner and polyester coil. Pack size: 100 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Macleods Pharma UK Limited
Wynyard Park House,
Wynyard Avenue,
Wynyard, Billingham,
TS22 5TB, United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 34771/0198
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
Date of first authorization: 20/12/2017
Date of last renewal: 03/03/2023
10 DATE OF REVISION OF THE TEXT
16/06/2026